Use of non-steroidal anti-infl ammatory drugs (NSAIDs) has been inversely associated with colorectal cancer; however, the association within colorectal subsites or among higher risk individuals is understudied. We investigated NSAID use and colorectal adenocarcinoma by subsite, and among individuals with a family history of colon cancer in the National Institutes of Health-AARP Diet and Health Study.
INTRODUCTION
Infl ammation is thought to have a critical role in the development of cancer, particularly colorectal cancer. Intrinsic infl ammation (via infl ammatory cells and mediators within the tumor microenvironment), as well as extrinsic infl ammation related to chronic infl ammatory conditions, is a contributor to tumor progression ( 1 ) . Epidemiological evidence indicates that proinfl ammatory conditions, such as infl ammatory bowel disease increase the risk of colorectal cancer ( 2 ) , whereas chronic use of non-steroidal antiinfl ammatory drugs (NSAIDs) may decrease risk ( 3, 4 ) . NSAIDs inhibit the cyclooxygenase (COX)-1 and COX-2 enzymes, which are involved in the synthesis of prostaglandins, leading to decreased activation of the infl ammatory response ( 2 ) , decreased epithelial proliferation and angiogenesis and increased apoptosis ( 5, 6 ) .
Th ere are limited data investigating whether use of NSAIDs, including the specifi c classes of NSAIDs (aspirin vs. non-aspirin), have diff erential eff ects within anatomic subsites of the colorectum. Some evidence from cohort studies suggests a stronger association between NSAID use and proximal vs. distal colon cancer ( 7, 8 ) , but the evidence regarding rectal cancer is mixed, likely attributable to small case numbers in the existing literature ( 7, 9 ) . Anatomic subsites within the colorectum derive from diff erent embryonic origins ( 10, 11 ) , and diff erent risk factors for colon vs. rectal cancer have been documented ( 12 ) . Furthermore, there are very little data on whether NSAIDs provide a chemoprotective benefi t among individuals at increased risk of developing colorectal cancer because of the presence of a family history of the disease. Given that colorectal cancer is the third most commonly diagnosed cancer in the United States ( 13 ) , the potential population attributable benefi t for chemoprevention is substantial in this subgroup of people.
In this investigation, we examined the association between aspirin and non-aspirin NSAID use and risk of adenocarcinoma of the colorectum by subsite in a large prospective study conducted in the United States. In addition, we conducted subanalyses of individuals with a family history of colon cancer in a fi rst-degree relative.
METHODS

Study population
Th e National Institutes of Health-AARP Diet and Health Study is a large prospective cohort of men and women, ages 50 to 71 years at recruitment, from six US states (California, Florida, Louisiana, New Jersey, North Carolina, and Pennsylvania) and two metropolitan areas (Atlanta, Georgia and Detroit, Michigan) and has been described in detail elsewhere ( 14 ) . A self-administered baseline questionnaire regarding demographic and lifestyle characteristics was completed in 1995 -1996. In total, 617,119 individuals returned the baseline questionnaire. A second questionnaire, hereaft er called the risk factor questionnaire, was mailed ~ 6 months aft er completion of the baseline questionnaire to collect additional information, including use of NSAIDs, and was returned by 334,908 individuals. For our analyses, we excluded individuals for whom either the baseline ( n = 6,959) or the risk factor questionnaire ( n = 3,424) was completed by proxies, those with prevalent cancer at the administration of the baseline ( n = 14,565) or risk factor questionnaire ( n = 4,297), those who had a death only report for any cancer ( n = 983), those with zero person years of follow-up ( n = 18), and those with missing data on use of both aspirin and non-aspirin NSAIDs ( n = 3,422). Th e resulting analytic cohort for our primary analysis included 301,240 participants (175,807 men and 125,433 women). Th e National Institutes of Health-AARP Diet and Health Study was approved by the Special Studies Institutional Review Board of the US National Cancer Institute.
Cohort follow-up and case ascertainment
Cohort members were followed for change of address using the US Postal Service. Annual linkage of the cohort to the US Social Security Administration Death Master File, follow-up searches of the National Death Index, cancer registry linkage, questionnaire responses, and responses to other mailings were used to obtain vital status. We identifi ed cancer cases through probabilistic linkage with state cancer registries. In addition to the eight original states from which the cohort recruited, our cancer registry ascertainment area was expanded to include Texas and Arizona, wherein participants have most commonly moved during follow-up. Approximately 4 % of participants were lost to follow-up as a result of moving out of the 10 states. Our case ascertainment method has been described in a previous study, which demonstrated that ~ 90 % of cancers were identifi ed through the cancer registries ( 15 ) .
Colorectal cancer end points were defi ned by anatomic site and histological code of the International Classifi cation of Diseases for Oncology ( 16 ) and included codes C180 -C189, C199, C209, and C260. We further classifi ed cases as those in the proximal colon (C180 -184), distal colon (C185 -187), and rectum (C199, C209). We only included fi rst primary diagnoses of adenocarcinoma; we excluded cases with unspecifi ed histologies ( n = 26), neuroendocrine tumors / carcinoids ( n = 87), lymphomas ( n = 25), sarcomas ( n = 9), squamous cell carcinomas ( n = 8), large cell carcinoma with rhabdoid phenotype ( n = 1), cloacogenic carcinoma ( n = 1), gastrinoma ( n = 1), cribriform carcinoma ( n = 1), and pigmented nevus ( n = 2). Follow-up for these analyses began on the date the risk factor questionnaire was received until censoring at the end of 2006 or when the participant moved out of the 10 state cancer registry areas, had a cancer diagnosis, or died, whichever came fi rst.
Assessment of NSAID use
Th e risk factor questionnaire assessed NSAID use (yes / no) during the previous 12 months and ascertained aspirin (generic aspirin and trade names) use and non-aspirin NSAID use separately. COX-2 inhibitors were not on the market at the time of questionnaire administration. Assessment of non-aspirin NSAID use was assessed in one question that listed examples of 19 non-aspirin NSAIDs (e.g., ibuprofen, sulindac, using both generic and trade names) and specifi cally excluded Tylenol, acetaminophen, and other pain relievers not listed. Our analyses examined aspirin use, non-aspirin NSAID use, and any NSAID use (defi ned as use of either of the previous two categories of drugs) separately. Participants were asked to mark how frequently they took each category of aspirin and non-aspirin NSAIDs individually: less than two times per month, two to three times per month, one to two times per week, three to four times per week, fi ve to six times per week, one time per day, or two or more times per day. Because of small numbers in some of the categories, we collapsed these into monthly ( ≤ 2 -3 times per month), weekly (1 -2 times per week to 5 -6 times per week), or daily use (1 or more times per day). Frequency of any NSAID use among individuals who reported use of both aspirin and non-aspirin NSAIDs was defaulted to the higher frequency (e.g., an individual reporting daily aspirin use and weekly non-aspirin NSAIDs use was categorized as a daily user of any NSAIDs).
Statistical analysis
Hazard ratios (HRs) and 95 % confi dence intervals (CIs) were estimated using Cox proportional hazards regression with person-years as the underlying time metric; analyses using age as COLON/SMALL BOWEL Ruder et al.
the underlying time metric yielded nearly identical HRs. Moreover, modeling the baseline hazard stratifi ed by age group and sex also yielded similar estimates to those using person-years as the underlying time metric. Th e proportional hazard assumption was verifi ed using a time interaction model. Tests for trend were calculated by assigning a categorical value to frequency of use where 0 = never use, 1 = monthly use, 2 = weekly use, and 3 = daily use.
To assess the relationship between NSAIDs use and colorectal cancer risk, we examined three separate models: (i) any use of aspirin or non-aspirin NSAIDs, (ii) use of aspirin, and (iii) use of nonaspirin NSAIDs. We assessed the relationship between frequency of use of NSAIDs (monthly, weekly, and daily) in the three models described above with never users as the referent group. Combining the monthly and never users in one referent group did not materially alter our results. Furthermore, we investigated use of NSAIDs among a subcohort of individuals who reported having a fi rst-degree relative with a history of colon cancer at the time of the baseline questionnaire ( n = 26,994).
Th e fi nal multivariate models only contained variables that changed the HR by 10 % or more or were established risk factors for colorectal cancer, and they included sex, body mass index (BMI), smoking, race, education, physical activity, alcohol consumption, smoking, and use of hormone replacement therapy. Variables that were investigated but did not alter the HR by 10 % or more included: personal history of diabetes or colorectal polyps, colorectal cancer screening practices, stage at diagnosis, and intake of calcium, iron, folate (including dietary and supplementary), whole grains, fi ber, total fat, saturated fat, red meat, processed meat, and total energy. Interactions for sex, BMI, smoking status, presence of a fi rst-degree relative with a history of colon cancer with NSAID use (any use, aspirin use, and non-aspirin NSAID use) were evaluated by including cross-product terms in multivariate models. Stratifi ed analyses by sex, BMI, smoking status, and presence of a fi rst-degree relative with history of colon cancer were also investigated. In addition, we conducted a lag analysis excluding the fi rst 2 years of follow-up. In attempt to establish a surrogate marker of longer-term NSAIDs use, we conducted a separate analysis of NSAID users who selfreported a history of heart disease in the baseline questionnaire relative to non-users with a history of heart disease, as these people were likely to have been advised to take aspirin for heart disease prevention.
To test for heterogeneity between the anatomic subsites (colon vs. rectum and proximal colon vs. distal colon), we calculated the weighted average of the two β coeffi cients from the Cox model, with weights being proportional to the inverse of the variances. We then calculated the following χ 2 statistic with one degree of freedom: wherein β i and σ i 2 are the coeffi cient and its variance for each subsite, and β -is the weighted average of the β coeffi cients. All statistical analyses were carried out using Statistical Analytic Systems soft ware version 9.1 (SAS Institute, Cary, NC).
RESULTS
Among the 301,240 eligible participants, we ascertained 3,894 incident colorectal cases (2,551 males and 1,343 females), of which 2,889 were colon (1,684 proximal, 1,118 distal, 87 lacked defi nite site information) and 1,005 were rectal cancers over 2,605,365 person years. Th e study cohort was predominately white with a mean age of 62.8 years. Th e incidence rate of colorectal cancer among cohort members was similar to the rate in a similarly aged Surveillance Epidemiology and End Results reference population ( 17 ) . A total of 13.4 % did not use aspirin or non-aspirin NSAIDs in the 12 months before administration of the risk factor questionnaire. Non-users were less likely to be male, married, a college graduate, and to be white ( Table 1 ) ( Table 2 ); these risks were evident for both men and women and the sex interactions with the outcome of colorectal cancer were not statistically signifi cant ( P -interaction any NSAIDs * sex = 0.70, P -interaction aspirin * sex = 0.41, P -interaction non-aspirin NSAIDs * sex = 0.92), nor were tests for interaction between BMI or smoking status and NSAID use (data not shown). Furthermore, analyses stratifi ed by sex, BMI, or smoking status revealed consistent associations across strata; and thus stratifi ed tables are not presented for these factors. For aspirin users, there was a statistically signifi cant reduction in rectal cancer risk (HR = 0.83, 95 % CI: 0.72, 0.96), but not colon cancer (HR = 0.94, 95 % CI: 0.86, 1.02). In contrast, the use of nonaspirin NSAIDs resulted in a reduced risk for all subsites within the colorectum ( Table 2 ). Assessment of individuals who used both aspirin and non-aspirin NSAIDs, individuals who used one type but not the other, as well as mutually adjusting for both classes of NSAIDs, did not materially alter our inferences.
Examining frequency of use of NSAIDs in relation to colorectal cancer risk revealed further decreases in risk as the frequency of use increased. Relative to no use, daily use of any NSAID was associated with a reduced risk of colorectal cancer across all subsites. Specifically, daily users of aspirin compared with non-users had a reduced risk of distal colon (HR = 0.84, 95 % CI: 0.71, 0.99, P-trend < 0.01) and rectal (HR = 0.76, 95 % CI: 0.64, 0.90, P -trend < 0.001) cancers ( Table 2 ) ; and daily use of non-aspirin NSAIDs compared with non-users resulted in risk reductions for both proximal and distal colon cancers (HR = 0.65, 95 % CI: 0.54, 0.78, P -trend < 0.0001; HR: 0.69, 95 % CI: 0.55, 0.87, P -trend < 0.001, respectively, Table 2 ). Interestingly, decreases in risk were also evident among those who took non-aspirin NSAIDs weekly or even monthly.
We repeated our analyses aft er excluding individuals who developed colorectal cancer during the fi rst 2 years of follow-up, as symptoms of undiagnosed colorectal cancer could alter participants ' use of NSAIDs; however, no appreciable changes were noted in the associations. No evidence of subsite heterogeneity was detected in any of the analyses. Th e heterogeneity test for cancer of the colon vs. rectum among daily aspirin users relative to never users approached statistical signifi cance ( P heterogeneity = 0.09); as did the test for colon vs. rectal cancer among daily non-aspirin NSAIDs users relative to non-users ( P heterogeneity = 0.06), but given the number of comparisons these results may be due to chance alone. In addition, no appreciable diff erences in HRs were detected among n = 41,404 individuals who reported a personal history of heart disease on the baseline questionnaire; of these individuals, 81 % reported taking aspirin in the past 12 months, of whom 61 % reported daily use.
Unadjusted analyses indicated that having a fi rst-degree relative with history of colon cancer was positively associated with colon cancer in our cohort (HR = 1.14, 95 % CI: 1.01, 1.29). Tests for interaction between presence of a fi rst-degree relative with a history of colon cancer and use of any NSAIDs, aspirin, or non-aspirin NSAIDs were statistically signifi cant among select combinations ( P -interaction aspirin * family history of colon cancer = 0.05 (for colon cancer), Pinteraction any NSAIDs * family history of colon cancer = 0.03, P -interaction aspirin * family history of colon cancer < 0.01 (for proximal colon cancer). Within the subgroup of individuals with a positive family history of colon cancer, use of any NSAIDs (yes / no) or use of non-aspirin NSAIDs specifi cally was not associated with colon or rectal cancer; although use of aspirin (yes / no) was associated with a reduction in rectal cancer risk (HR = 0.60, 95 % CI: 0.37, 0.98, Table 3 ). Investigating frequency of use revealed further associations, including a reduced risk for rectal cancer among daily users of aspirin compared with non-users (HR = 0.38 95 % CI: 0.19, 0.78, P -trend = 0.01), and a reduced risk for proximal colon cancer among weekly and daily users of non-aspirin NSAIDs (weekly use: HR = 0.54 95 % CI: 0.31 -0.96; daily use: HR = 0.44 95 % CI: 0.22, 0.88, P -trend = 0.01). 
DISCUSSION
In this large prospective study with 2,605,365 person years of follow-up over 10 years, use of any NSAIDs was associated with a 20 % reduced risk of colorectal cancer. Furthermore, increased frequency of use of both classes of NSAIDs was associated with lower risks across anatomic subsites of the colorectum. Within individuals with a fi rst-degree relative with a history of colon cancer, daily aspirin use (yes / no) was associated with a 40 % reduction in rectal cancer risk, and weekly (defi ned as 1 -2 times per week to 5 -6 times per week) or daily use of non-aspirin NSAIDs reduced the risk of proximal colon cancer by 46 and 56 % , respectively. However, the CIs for the estimates among individuals with a positive family history were wide; thus, the risk reduction among the general study population and individuals with a family history of colon cancer were not statistically signifi cantly diff erent from each other. A number of previously published cohort studies have assessed aspirin or non-aspirin NSAIDs use and incidence of colorectal cancer ( 8,9,18 -26 ) , although only two cohort studies, the Nurses ' Health Study (NHS) ( 18, 20 ) and the Health Professionals ' Followup Study (HPFS) ( 21 ), were defi ned as " good " quality in the US Preventive Services Task Force reports on the use of aspirin and non-aspirin NSAIDs for primary prevention of colorectal cancer ( 3, 4 ) . To the best of our knowledge, only one new cohort study of primary, incident colorectal cancer ( 7 ) has been published since the US Preventive Services Task Force ended accruement for inclusion in its 2007 systematic reviews ( 3, 4 ) , although an update to the HPFS was published in 2008 (9) .
Th e NHS, which examined 962 colorectal cancer cases over 20 years of follow-up in nearly 83,000 average risk women reported a dose-dependent reduction in colorectal cancer risk with years of regular aspirin use (defi ned as consumption of two or more standard tablets per week), as well as a reduction with increasing dose per week. However, the authors reported a reduced risk in colon cancer but not rectal cancer in site-specifi c analyses ( 18 ), whereas we noted reductions in risks for both colon and rectal cancers. Results from 47,363 males enrolled in the HPFS were comparable to those from the NHS; although aspirin use was associated with decreased rectal cancer risk, and this association was stronger than that noted for proximal or distal colon cancers ( 9 ). However, the authors cautioned that a limited number of cases were available for each subsite and confi rmatory studies are needed. Tests for subsite heterogeneity were not reported in the HPFS, but the overlapping CIs suggest that the diff erence was not statistically signifi cant.
Results from the Iowa Women ' s Health Study reported greater reductions in risk of proximal colon cancer compared with cancer of the distal colon and rectum among aspirin users, although that study had fewer cases than HPFS and our study ( 7 ) . Our investigation found reductions in colon and rectal cancers among individuals who reported aspirin and non-aspirin NSAIDs use, particularly at increased frequencies of use. Results from our study suggesting that monthly use of any NSAID or non-aspirin NSAIDs (defi ned as no greater than 2 -3 times per month) was associated with protection from colorectal cancer was unexpected; but demonstrates that it is possible that use of NSAIDs just 2 -3 times per month could be enough to elicit an eff ect. However, it is also possible that participants misclassifi ed their exposure or that current monthly users may have used NSAIDs frequently enough in the past to confer a protective benefi t. Furthermore, as the frequency of " use of any NSAID " defaulted to the higher frequency if an individual reported use of both classes of NSAIDs, these results could be biased by the individuals who were taking both aspirin and non-aspirin NSAIDs monthly; however, this is unlikely as only 1.2 % (data not shown) of the monthly users reported use of both classes of NSAIDs.
Unlike the previous cohort studies, which had fewer than 230 cases of rectal cancer; data were available for over 1,000 cases of rectal cancer in our study. Our data support the observation made in the HPFS regarding a stronger inverse association between aspirin use and rectal cancer than that observed for cancer of the proximal or distal colon. Although we noted a greater reduction in risk for rectal cancer than colon cancer with daily aspirin use, the evidence for subsite heterogeneity did not reach statistical significance, suggesting that the magnitudes of these associations are not materially diff erent. Results from a population-based case -control study of incident distal colorectal cancer also reported more potent eff ects of aspirin use for rectal and rectosigmoid cancers than for sigmoid cancer among 1,057 incident cases and 1,019 HRs and 95 % CIs come from models adjusted for age at cohort entry, sex, cigarette smoking status, race, physical activity level, BMI at study baseline, alcohol, education, race, physical activity level, BMI at study baseline, and use of hormone replacement therapy. reminder to interpret these results with caution, but if true, these results could tip the risk-benefi t equation in favor of use of these drugs in high-risk groups. Although the published evidence for a chemopreventive role of NSAIDs among individuals at an increased risk for colorectal cancer because of a family history of this disease is limited, evidence for groups with known hereditary conditions linked to colorectal cancer is available; e.g., use of celecoxib or sulindac reduced the incidence of colorectal polyps in patients with familial adenomatous polyposis ( 35, 36 ) . However, no protective eff ect of 600 mg aspirin was shown in a randomized clinical trial of 1,071 carriers of Lynch syndrome (hereditary nonpolyposis colorectal cancer) ( 37 ) . Although we lacked information on whether individuals in our study had been diagnosed with either of these hereditary conditions, familial adenomatous polyposis and Lynch Syndrome are thought to contribute to < 5 -6 % of all colorectal cancers in the general population ( 12 ) . Furthermore, colorectal cancer related to these genetic conditions typically occurs at a young age of onset; the median age of individuals with a family history of colon cancer in our study was 62.8 years at the time the risk factor questionnaire was administered.
A limitation of our study is the absence of data on duration of NSAIDs use. Previous studies have suggested that duration of aspirin use of 10 years or more and duration of non-aspirin NSAIDs use of 2 -5 years and longer is required to achieve a reduction in colorectal cancer risk ( 9,18,20,21,38 -41 ) . Subanalysis of individuals in our cohort with self-reported history of heart disease at baseline, our rough proxy for longer duration of use, yielded HRs similar to those of the overall cohort. In addition, use of NSAIDs was only ascertained at one time point and we lacked information regarding NSAIDs use during the cohort follow-up period. Th ere is the distinct possibility that individuals changed their pattern of NSAID use during the follow-up period; this would likely bias the results toward the null. Our study also lacked information on dose and indication for NSAIDs use. In particular, we were unable to distinguish between use of low-dose aspirin (typically 81 mg) vs. full-strength (typically 325 mg) tablets. Two randomized trials of aspirin and colorectal cancer incidence have failed to demonstrate a benefi t of low-dose aspirin therapy aft er 5 and 10 years of followup ( 42, 43 ) , and cohort studies suggest that dosage much greater than that achieved with daily low-dose aspirin use is necessary to derive colorectal cancer protection ( 9, 18, 21 ) . Recently, however, results from 20-year follow-up of fi ve randomized trials indicated that use of at least 75 mg daily was eff ective in the reduction of both colorectal cancer incidence and mortality ( 33 ) . Th us, the possible attenuation of eff ect due to heterogeneity in dose among aspirin users in our study may be less than previously assumed. All data in our investigation were self-reported as part of a questionnaire; thus, misreporting of both exposure and confounding variables is possible, as well as the potential for residual confounding. Finally, our cohort was comprised of older adults (mean age 62.8 years), and results may not be applicable to other age groups.
Our study has numerous strengths, including, being the largest cohort to date, having evaluated the association of NSAID type and colorectal cancer by anatomic subsite as reported in state controls from North Carolina ( 27 ) . Although neither the NHS nor HPFS reported the relationship between non-aspirin NSAIDs use and colon subsites, Smalley et al. ( 8 ) noted the protective benefi t of non-aspirin NSAIDs use was more pronounced for proximal colon cancer compared with distal colon cancer, as did results from the Iowa Women ' s Health Study ( 7 ) and our study. Proximal colon tissue has an embryonic origin diff erent from that of tissue distal to the splenic fl exure ( 10, 11 ) and cancers of the proximal colon, distal colon, and rectum diff er in regard to their epidemiological, clinical, and histological parameters ( 27 -30 ) . Th us, it is possible that investigation of risk factors, such as NSAID use, by colorectal subsite could provide valuable insight in to the etiology of colorectal cancer. Specifi c to NSAID use, COX-2 expression may vary depending on colorectal tumor location ( 31, 32 ) , although it is unclear whether it is over-or under-expressed in rectal tumors compared with colon tumors. In the future, if confi rmatory studies continue to show a more protective eff ect on the proximal colon and safer COX inhibitors are available in the marketplace, then more widespread use of this class of drugs may be warranted given that colonoscopy may be less eff ective in identifying right-sided neoplasia. Indeed, results from a recent pooled analysis of fi ve randomized trials of daily aspirin use indicated that the decrease in colon cancer risk was driven by reductions in cancer of the proximal, but not distal colon. In addition, no reduction in rectal cancer risk with aspirin use was observed in the pooled analysis. Th e authors hypothesize that overexpression of COX-2 in the distal colon may lead to less complete COX-2 inhibition with aspirin use in the distal colon relative to the proximal colon ( 33 ) . Th e lack of an association of distal and rectal cancer with aspirin use in the combined analyses of these trials is intriguing, although the small case numbers must be noted: in total there were only 100 cases of distal colon cancer and 119 cases of rectal cancer. Furthermore, trial participants were overwhelmingly male.
A unique feature of our study was the ability to analyze over 26,000 individuals with a higher risk of colorectal cancer because of having a fi rst-degree relative with this malignancy. Few studies have examined the association of NSAIDs use in this higher risk group. Coogan et al. ( 34 ) examined two case -control studies to assess whether family history of colorectal cancer in a parent or sibling modifi ed the association of NSAIDs use with colorectal cancer; although they reported similar risk reductions in the two risk groups, both studies had fewer than 200 cases with a family history of the disease. Our results suggest that the protective benefi t of NSAIDs among individuals with a positive family history of colon cancer is similar to, if not greater than, the risk reduction experienced in the general population. However, the risk reductions among the family history subgroup were not statistically signifi cantly lower than those of the general study population, although the small number of cases for each subsite among the positive family history group must be noted. Overall, the risk of developing colon cancer among those with a positive family history was lower than expected. We attribute this to bias given the older age of participants at study entry, as well as possible diff erential screening before study entry among individuals with a family history of the disease. Th e limited case numbers is an important COLON/SMALL BOWEL NSAIDs Use and Colorectal Cancer Risk cancer registries. Our analysis of NSAIDs use and colorectal cancer risk among individuals with a fi rst-degree relative with history of the disease is one of only a few studies to examine this higher risk subgroup. Although some of the risk estimates suggest a greater risk reduction of colorectal cancer in those with a positive family history of this malignancy, some of the case numbers for daily users with a positive family history were small and the diff erences in the HRs with the general study population were not statistically signifi cant. In addition, multiple interactions were tested and the possibility of chance fi ndings cannot be eliminated. Th us, the fi ndings for NSAID use among individuals with a family history of colon cancer should be interpreted with caution. Last, the risks associated with long-term NSAIDs use, including gastrointestinal and cardiovascular complications are well documented and serious ( 3, 4 ) . Recommendation of chemopreventive NSAIDs use among individuals with a family history of colorectal cancer at this time is premature.
In summary, our results suggest that weekly or daily use of NSAIDs is associated with colorectal cancer protection in the general population, as well as in individuals with a fi rst-degree relative with colon cancer. Th e strength of the association varies by drug class, but generally a dose -response relationship is observed between increased frequency of use and cancer protection. Th e potential harms associated with NSAIDs use must be considered before translating these results into clinical practice.
